SciSparc Ltd.
corporate_fare Company Profile
SciSparc Ltd. (NASDAQ:SPRC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for SPRC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-24, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for SPRC spans F-3/A, 6-K, 144, 20-F.
Recent high-impact activity:
- SciSparc-Clearmind MDMA-PEA Patent Published as FDA Finalizes Psychedelic Guidance
- SciSparc Registers 2.56M Shares for Resale, Potential 440% Dilution
- NeuroThera's C$5.4M Financing Locks in C$30M Valuation for SciSparc Stake
- SciSparc's NeuroThera Launches Phase IIb Trial at Yale for Tourette Syndrome, Reveals 21% Tic Reduction in Prior Study
- NeuroThera's Quantum Platform Achieves Full Clinical Data Workflow Milestone
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for SPRC, detected from its recent SEC filings · based on capital-structure filings through 2026-08-19.
Resale Registration of 2.56M Shares · Potential 440% Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
SPRC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.